David Rikard Martinsson Holmdahl
Gründer bei Redoxis AB
Profil
Dr. David Rikard M.
Holmdahl, MD PhD, is a Professor at Karolinska Institutet, Chairman at Redoxis AB, and a Professor at University of Turku.
He is on the Board of Directors at ProNoxis AB.
Dr. Holmdahl was previously employed as a Professor by University of Lund.
Aktive Positionen von David Rikard Martinsson Holmdahl
| Unternehmen | Position | Beginn |
|---|---|---|
Redoxis AB
 Redoxis AB Medical SpecialtiesHealth Technology Redoxis AB focuses on preclinical drug development and validation in autoimmune diseases. The firm focuses on preclinical development of small molecules that target molecular pathways in the immunological responses associated with autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. The company was founded by David Rikard Martinsson Holmdahl and Jan Peter Olofsson in 2007 and is headquartered in Gothenburg, Sweden. | Gründer | 01.01.2007 |
| Karolinska Institutet | Corporate Officer/Principal | 22.12.2009 |
| University of Turku | Corporate Officer/Principal | 26.07.2011 |
Ehemalige bekannte Positionen von David Rikard Martinsson Holmdahl
| Unternehmen | Position | Ende |
|---|---|---|
| University of Lund | Corporate Officer/Principal | 01.01.2007 |
ProNoxis AB
 ProNoxis AB Pharmaceuticals: MajorHealth Technology ProNoxis AB develops small-molecule drugs to treat chronic inflammation. The company was founded in 2009 and is headquartered in Lund, Sweden. | Direktor/Vorstandsmitglied | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
ProNoxis AB
ProNoxis AB Pharmaceuticals: MajorHealth Technology ProNoxis AB develops small-molecule drugs to treat chronic inflammation. The company was founded in 2009 and is headquartered in Lund, Sweden. | Health Technology |
Redoxis AB
Redoxis AB Medical SpecialtiesHealth Technology Redoxis AB focuses on preclinical drug development and validation in autoimmune diseases. The firm focuses on preclinical development of small molecules that target molecular pathways in the immunological responses associated with autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. The company was founded by David Rikard Martinsson Holmdahl and Jan Peter Olofsson in 2007 and is headquartered in Gothenburg, Sweden. | Health Technology |
